Pro32Thr Polymorphism of Inosine Triphosphate Pyrophosphatase Gene Predicts Efficacy of Low‐Dose Azathioprine for Patients With Systemic Lupus Erythematosus | Zendy

Okada Y | Zendy; Nakamura K | Zendy; Hiromura K | Zendy; Nojima Y | Zendy; Horiuchi R | Zendy; Yamamoto K | Zendy

Premium

Pro32Thr Polymorphism of Inosine Triphosphate Pyrophosphatase Gene Predicts Efficacy of Low‐Dose Azathioprine for Patients With Systemic Lupus Erythematosus

Author(s) -

Okada Y,

Nakamura K,

Hiromura K,

Nojima Y,

Horiuchi R,

Yamamoto K

Publication year - 2009

Publication title -

clinical pharmacology and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.941

H-Index - 188

eISSN - 1532-6535

pISSN - 0009-9236

DOI - 10.1038/clpt.2008.261

Subject(s) - itpa , pyrophosphatase , azathioprine , medicine , pharmacology , single nucleotide polymorphism , gene polymorphism , polymorphism (computer science) , systemic lupus erythematosus , immunology , gastroenterology , gene , biology , disease , allele , genotype , biochemistry , enzyme , virus , hepatitis c virus , ribavirin

We evaluated the relationship between the efficacy of low‐dose azathioprine (AZA) therapy and the inosine triphosphate pyrophosphatase ( ITPA ) 94C>A (Pro32Thr) polymorphism in patients with systemic lupus erythematosus (SLE). We performed a multiple regression analysis to assess the influence of various factors on the reduction in SLE disease activity index (SLEDAI) scores. The ITPA 94C>A polymorphism had the highest correlation with the change in SLEDAI score ( r = 0.354, P = 0.006). Clinical Pharmacology & Therapeutics (2009); 85 , 5, 527–530 doi: 10.1038/clpt.2008.261

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research